Pfizer Presents Overall Survival Data For Sutent? Versus Interferon-Alfa - Fi bi13652150 Results from a landmark study have shown that sunitinib (SUTENT?) has demonstrated overall survival greater than two years patients metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer

Banned cancer drugs better than NHS ones (Times Online) bi13652150 The National Health Service providing dying cancer patients drugs that are five times less effective than those available privately and refusing to treat them they try to buy medicines themselves

Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic bi13652150 Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company's human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by the human immune system vitro

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than St bi13652150 EAST HANOVER, N.J. ( Map ) - EAST HANOVER, N.J. , June 13 /PRNewswire/ -- New data from a large, international clinical trial find that patients newly diagnosed chronic myeloid leukemia who received Gleevec(R) (imatinib meslyate) tablets at 800 mg/day as initial treatment achieved clinical milestones significantly faster than those receiving the standard 400 mg/day dose

Helix BioPharma product development update, quarterly highlights and financia bi13652150 Helix BioPharma Corp. , a biopharmaceutical company specializing the field of cancer therapy, today announced product development progress, quarterly highlights and financial results for the three and nine month periods ended April 30, 2008

My Pharmiweb.com (PharmiWeb) bi13652150 Kidney cancer patients who receive treatment the orally-administered tyrosine kinase inhibitor sunitinib (Sutent) are living twice as long as patients who receive only interferon treatment, according to data from a Phase III study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) Chicago

Results Of A Phase 3 Study Show TORISEL Significantly Improved Progression-fr bi13652150 Data presented from a phase 3 clinical trial at the 44th Annual Meeting of the American Society of Clinical Oncology show that patients relapsed and/or refractory (failed front line therapy and unresponsive to most recent treatment) mantle cell lymphoma (MCL) treated TORISEL (temsirolimus),..

11 June 2008 (PharmiWeb) bi13652150 Basel, May 30, 2008. Data presented at the largest oncology meeting the world, the American Society of Clinical Oncology (ASCO), shows that the costs of managing side effects patients metastatic renal cell cancer (mRCC) treated sunitinib (Sutent®) are two to three times greater than they were treated the combination of Avastin and interferon (IFN), a combination ..

VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising Immune Respo bi13652150 VioQuest Pharmaceuticals (OTCBB: VOQP) today reported updated data from a Phase 1 dose escalation study evaluating Lenocta(TM) (sodium stibogluconate) combination interferon -2b (IFN -2b) patients various advanced solid tumors. Data from 21 patients were presented during an oral session titled "Developmental Therapeutics: Immunotherapy," by Aung Naing, MD, assistant ..

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Po bi13652150 Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that a presentation was made today at the 3rd International Workshop on Hepatitis C, Resistance and New Compounds Boston, Mass. on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs

Banned cancer drugs better than NHS ones (Times Online) bi13652150 The National Health Service providing dying cancer patients drugs that are five times less effective than those available privately and refusing to treat them they try to buy medicines themselves

Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic bi13652150 Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company's human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by the human immune system vitro

Antique Furniture Chairs - Home